Literature DB >> 21720886

Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A.

Stefania Sarno1, Marco Mazzorana, Ryan Traynor, Maria Ruzzene, Giorgio Cozza, Mario A Pagano, Flavio Meggio, Giuseppe Zagotto, Roberto Battistutta, Lorenzo A Pinna.   

Abstract

8-hydroxy-4-methyl-9-nitrobenzo(g)chromen-2-one (NBC) has been found to be a fairly potent ATP site-directed inhibitor of protein kinase CK2 (Ki = 0.22 μM). Here, we show that NBC also inhibits PIM kinases, especially PIM1 and PIM3, the latter as potently as CK2. Upon removal of the nitro group, to give 8-hydroxy-4-methyl-benzo(g)chromen-2-one (here referred to as "denitro NBC", dNBC), the inhibitory power toward CK2 is almost entirely lost (IC(50) > 30 μM) whereas that toward PIM1 and PIM3 is maintained; in addition, dNBC is a potent inhibitor of a number of other kinases that are weakly inhibited or unaffected by NBC, with special reference to DYRK1A whose IC(50) values with NBC and dNBC are 15 and 0.60 μM, respectively. Therefore, the observation that NBC, unlike dNBC, is a potent inducer of apoptosis is consistent with the notion that this effect is mediated by inhibition of endogenous CK2. The structural features underlying NBC selectivity have been revealed by inspecting its 3D structure in complex with the catalytic subunit of Z. mays CK2. The crucial role of the nitro group is exerted both through a direct electrostatic interaction with the side chain of Lys68 and, indirectly, by enhancing the acidic dissociation constant of the adjacent hydroxyl group which interacts with a conserved water molecule in the deepest part of the cavity. By contrast, the very same nitro group is deleterious for the binding to the active site of DYRK1A, as disclosed by molecular docking. This provides the rationale for preferential inhibition of DYRK1A by dNBC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720886     DOI: 10.1007/s00018-011-0758-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  35 in total

Review 1.  Emergence of protein kinase CK2 as a key target in cancer therapy.

Authors:  Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed
Journal:  Biofactors       Date:  2010 May-Jun       Impact factor: 6.113

Review 2.  The druggable genome.

Authors:  Andrew L Hopkins; Colin R Groom
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

3.  Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.

Authors:  Giorgio Cozza; Paolo Bonvini; Elisa Zorzi; Giorgia Poletto; Mario A Pagano; Stefania Sarno; Arianna Donella-Deana; Giuseppe Zagotto; Angelo Rosolen; Lorenzo A Pinna; Flavio Meggio; Stefano Moro
Journal:  J Med Chem       Date:  2006-04-20       Impact factor: 7.446

4.  Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases.

Authors:  Piotr P Graczyk
Journal:  J Med Chem       Date:  2007-10-19       Impact factor: 7.446

5.  Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis.

Authors:  Mauro Salvi; Stefania Sarno; Luca Cesaro; Hideji Nakamura; Lorenzo A Pinna
Journal:  Biochim Biophys Acta       Date:  2009-01-31

Review 6.  Addiction to protein kinase CK2: a common denominator of diverse cancer cells?

Authors:  Maria Ruzzene; Lorenzo A Pinna
Journal:  Biochim Biophys Acta       Date:  2009-08-06

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  PHENIX: a comprehensive Python-based system for macromolecular structure solution.

Authors:  Paul D Adams; Pavel V Afonine; Gábor Bunkóczi; Vincent B Chen; Ian W Davis; Nathaniel Echols; Jeffrey J Headd; Li-Wei Hung; Gary J Kapral; Ralf W Grosse-Kunstleve; Airlie J McCoy; Nigel W Moriarty; Robert Oeffner; Randy J Read; David C Richardson; Jane S Richardson; Thomas C Terwilliger; Peter H Zwart
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

Review 9.  Protein kinase CK2 as a druggable target.

Authors:  Stefania Sarno; Lorenzo A Pinna
Journal:  Mol Biosyst       Date:  2008-06-12

10.  Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships.

Authors:  Adriana Chilin; Roberto Battistutta; Andrea Bortolato; Giorgio Cozza; Samuele Zanatta; Giorgia Poletto; Marco Mazzorana; Giuseppe Zagotto; Eugenio Uriarte; Adriano Guiotto; Lorenzo A Pinna; Flavio Meggio; Stefano Moro
Journal:  J Med Chem       Date:  2008-02-06       Impact factor: 7.446

View more
  11 in total

1.  Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential.

Authors:  Giorgio Cozza; Cristina Girardi; Alessandro Ranchio; Graziano Lolli; Stefania Sarno; Andrzej Orzeszko; Zygmunt Kazimierczuk; Roberto Battistutta; Maria Ruzzene; Lorenzo A Pinna
Journal:  Cell Mol Life Sci       Date:  2014-01-18       Impact factor: 9.261

2.  Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.

Authors:  Kunal Kumar; Peng Wang; Roberto Sanchez; Ethan A Swartz; Andrew F Stewart; Robert J DeVita
Journal:  J Med Chem       Date:  2018-08-21       Impact factor: 7.446

3.  Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.

Authors:  Kunal Kumar; Peter Man-Un Ung; Peng Wang; Hui Wang; Hailing Li; Mary K Andrews; Andrew F Stewart; Avner Schlessinger; Robert J DeVita
Journal:  Eur J Med Chem       Date:  2018-08-22       Impact factor: 6.514

4.  Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.

Authors:  Mir Mohammad Shahroz; Hemant Kumar Sharma; Abdulmalik S A Altamimi; Mubarak A Alamri; Abuzer Ali; Amena Ali; Safar Alqahtani; Ali Altharawi; Alhumaidi B Alabbas; Manal A Alossaimi; Yassine Riadi; Ahmad Firoz; Obaid Afzal
Journal:  Molecules       Date:  2022-02-09       Impact factor: 4.411

Review 5.  Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Authors:  Breland Smith; Federico Medda; Vijay Gokhale; Travis Dunckley; Christopher Hulme
Journal:  ACS Chem Neurosci       Date:  2012-08-28       Impact factor: 4.418

6.  Structure-Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation.

Authors:  Kunal Kumar; Peng Wang; Ethan A Swartz; Susmita Khamrui; Cody Secor; Michael B Lazarus; Roberto Sanchez; Andrew F Stewart; Robert J DeVita
Journal:  Molecules       Date:  2020-04-23       Impact factor: 4.411

7.  Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.

Authors:  Kunal Kumar; Peng Wang; Jessica Wilson; Viktor Zlatanic; Cecilia Berrouet; Susmita Khamrui; Cody Secor; Ethan A Swartz; Michael Lazarus; Roberto Sanchez; Andrew F Stewart; Adolfo Garcia-Ocana; Robert J DeVita
Journal:  J Med Chem       Date:  2020-02-19       Impact factor: 7.446

8.  Synthesis and properties of a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2).

Authors:  Giorgio Cozza; Sofia Zanin; Renate Determann; Maria Ruzzene; Conrad Kunick; Lorenzo A Pinna
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

9.  Hologram QSAR models of a series of 6-arylquinazolin-4-amine inhibitors of a new Alzheimer's disease target: dual specificity tyrosine-phosphorylation-regulated kinase-1A enzyme.

Authors:  Felipe Dias Leal; Camilo Henrique da Silva Lima; Ricardo Bicca de Alencastro; Helena Carla Castro; Carlos Rangel Rodrigues; Magaly Girão Albuquerque
Journal:  Int J Mol Sci       Date:  2015-03-06       Impact factor: 5.923

10.  The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation.

Authors:  Giorgio Cozza; Andrea Venerando; Stefania Sarno; Lorenzo A Pinna
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.